Zogenix, a global biopharmaceutical company specializing in the treatment of epilepsy associated with Dravet syndrome, has been acquired by UCB following an agreement today. The overall transaction value is to be around 1.9B dollars. The Belgian company will offer to purchase all Zogenix’s outstanding shares for $26 in cash. The deal has been unanimously authorized by the boards of directors of both companies. And today, Zogenix’s stock pleases investors as it has grown by 60%. Now the price per share is $25.05. The last time the stock reached such a price was in June 2020.
The deal will strengthen the Belgian company’s position as a leader in, and ongoing dedication to meeting the unmet needs of patients suffering from rare types of epilepsy, by including FINTEPLA in UCB’s product line. This medicine was approved by the FDA, EMA in 2020, and it is currently undergoing regulatory evaluation in Japan. The Executive Vice President of UCB is excited to collaborate with the Zogenix team. Their objective is to provide patients access to medications as quickly as possible and to broaden their influence so that a huge number of people can benefit.